5 completed, 1 unknown. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 5, Unknown 1 |
Follow tafluprost: new trials by email Literature Review of tafluprost trials Research Report on tafluprost
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL, A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL - Open-angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Santen Pharmaceutical Co., Ltd. | 219 | 2019-01-20 | 2023-07-14 |
| Switching From Preserved to Preserved-free Treatments for Glaucoma. Tafluprost, Latanoprost - Glaucoma | Phase 3 | Unknown | Paolo Fogagnolo | 40 | 2012-05-01 | 2014-05-16 |
| Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations Timolol and Tafluprost, Fixed Dose Combination of tafluprost and timolol - Ocular Hypertension, Open-angle Glaucoma | Phase 3 | Completed | Santen Oy | 401 | 2011-03-01 | 2012-06-08 |
| Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies Timolol/ FDC/ Placebo/ Tafluprost - Ocular Hypertension, Open-angle Glaucoma | Phase 3 | Completed | Santen Oy | 600 | 2011-02-01 | 2013-03-13 |
| Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops tafluprost - Ocular Hypertension, Open-Angle Glaucoma | Phase 3 | Completed | Santen Oy | 185 | 2010-04-01 | 2013-05-31 |
| Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops tafluprost - Ocular Hypertension, Open-Angle Glaucoma | Phase 3 | Completed | Santen Oy | 150 | 2008-01-01 | 2009-01-12 |
Glaucoma, Open-Angle (5) · Ocular Hypertension (5) · Glaucoma (2)
Santen Oy (4) · Paolo Fogagnolo (1) · Santen Pharmaceutical Co., Ltd. (1)
Finland (2) · China (1) · Hungary (1) · Italy (1)
Auli Ropo, M.D. (2) · Clemens Vass, M.D. (1) · Eva Ruzickova, M.D. (1) · Evgeniy Egorov, Professor (1) · Guna Laganovska, M.D. (1) · Hannu Uusitalo, M.D., Prof. (1) · Hannu Uusitalo, Professor (1) · Luca Rossetti, MD (1) · Maria L. Ribeiro, M.D. (1) · Marieta Kostianeva, M.D. (1)